Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q1 2025 · 10-Q
Revenue$10.36B$10.36B+4.0% vs Q1 2024 Net Income$1.33B$1.33B+8.2% vs Q1 2024 EPS Diluted$0.76$0.76+8.6% vs Q1 2024 Operating Income$1,693,000,000+22.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Free Cash Flowderived$933,000,000+48.8% Margins · derivedOperating margin16.3%+2.4 pt vs Q1 2024
Net margin12.8%+0.5 pt vs Q1 2024
ended Mar 31, 2025 · filed Apr 30, 2025 · 30 d after period end